Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 0.53% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 2.45% YoY) and the FY2025 annual result came in at $7.6 million, up 5.09% from the prior year.
• Depreciation & Amortization (CF) retreated to $1.9 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q3 2025 to a low of $72000.0 in Q3 2022.
• A 5-year average of $1.5 million and a median of $1.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 61.9% — and 2023, when it jumped 2354.17%.
• Tracing CTKB's Depreciation & Amortization (CF) over 5 years: stood at $761000.0 in 2022, then surged by 114.32% to $1.6 million in 2023, then increased by 13.67% to $1.9 million in 2024, then advanced by 2.27% to $1.9 million in 2025, then decreased by 1.64% to $1.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.